Business description
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines, including smallpox, monkeypox, rabies, tick-borne encephalitis, and Ebola vaccines. It is advancing MVA-BN RSV in Phase III trials for respiratory syncytial virus and ABNCoV2 for SARS-CoV-2. The company operates globally and is headquartered in Hellerup, Denmark.
Management board & Supervisory board
| CEO |
| Paul Chaplin |
| Management board |
| Henrik Juuel, Jean-Christophe May, Anu Helena Kerns, Russell Thirsk |
| Supervisory board |
| Luc Debruyne, Anders Gersel Pedersen, Frank Verwiel, Anne Louise Eberhard, Heidi Hunter, Johan van Hoof, Montse Montaner, Linette Munksgaard Andersen, Thomas Alex Bennekov, Anja Gjøl, Karen Merete Jensen |
Company data
| Name: |
Bavarian Nordic A/S |
| Address: |
Philip Heymans Alle 3,DK-2900 Hellerup Denmark |
| Phone: |
+45-3326-8383 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
www.bavarian-nordic.com |
| Industry: |
Biotechnology |
| Sector: |
Biotechnology |
| Sub sector: |
Biotechnology |
| End of financial year: |
12/31 |
| Free Float: |
- |
| IPO date: |
- |
